News

Press Release | Jan 30, 2017

An experienced management group led by Joseph M. Limber, in partnership with Ampersand Capital Partners and 1315 Capital, has entered into a definitive agreement to acquire the commercial laboratory of Genoptix, Inc., a Novartis company that specializes in oncology diagnostics and informatics services. This transaction is expected to close in the first quarter of 2017

Press Release | Jan 17, 2017

Encore Dermatology Inc., a privately held dermatology company that specializes in developing and commercializing novel prescription products for improving skin health, announced today the availability of TridesilonTM (desonide) Cream, 0.05% in a 60g tube. TridesilonTM Cream, 0.05% is a low-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

News | Jan 13, 2017

Past and present commissioners of the U.S. Food and Drug Administration, both with ties to Duke University, are among the speakers headlining the Council for Entrepreneurial Development’s 26th annual Life Science Conference next month in Raleigh. Confirmed speakers at the conference include Adele Oliva, Ibraheem Badejo, and James C. Greenwood.

News | Jun 15, 2016

1315 Capital today announced the final closing of its $200 million inaugural fund. The fund is led by seasoned healthcare investors and 1315 Capital’s Co-Founders, Adele Oliva and Michael Koby, and includes a select group of high quality investors, including endowments, foundations, state and corporate pension funds, and family offices.

News | Apr 19, 2016

Onkos Surgical and Vivex Biomedical, Inc. have come together to provide a portfolio of tissue products to support the needs of musculoskeletal oncologists and their patients. This commitment strengthens Onkos Surgical’s ability to enhance outcomes, decrease complications and improve recovery following musculoskeletal tumor and limb salvage surgery.

Pages 1 2 3 4 5